NCT05823480 2024-09-19Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDSCity of Hope Medical CenterPhase 1 Withdrawn
NCT05807126 2024-05-02Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsNational Cancer Institute (NCI)Phase 1 Withdrawn